MedTrace Logo

Everolimus and Tacrolimus Combination for Regression of Left Ventricular Hypertrophy in Renal Transplants

NCT03415750 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-01-08

No results posted yet for this study

Summary

Clinical study with two parallel group to compare the efficacy of everolimus combination + tacrolimus in regression of left ventricular hypertrophy vs tacrolimus + mycophenolate mofetil in renal transplant patients in the maintenance phase.

Conditions

  • Hypertrophy, Left Ventricular

Interventions

DRUG

Everolimus

Conversion from Mycophenolate mofetil to Everolimus

DRUG

Mycophenolate mofetil

Patients will remain in Tacrolimus + Mycophenolate mofetil

DRUG

Tacrolimus

Sponsors & Collaborators

  • Edoardo Melilli

    lead OTHER

Principal Investigators

  • Edoardo Melilli, MD · Hospital Universitari de Bellvitge

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2020-05-31
Completion
2020-05-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03415750 on ClinicalTrials.gov